Menu

Recent Interviews

Jerre Foo, Corporate Development Executive, Silkroad Nickel

Jerre Foo
Corporate Development Executive | Silkroad Nickel
50 Armenian Street #03-04, 179938 Singapore (SGP)

enquiries@silkroadnickel.com

+65 6327 8971

Silkroad Nickel: 'The course is set for dynamic profit growth.'


Dr. Thomas Gutschlag, CEO, Deutsche Rohstoff AG

Dr. Thomas Gutschlag
CEO | Deutsche Rohstoff AG
Q7, 24, 68161 Mannheim (D)

info@rohstoff.de

+49 621 490 817 0

Interview Deutsche Rohstoff AG: "We can imagine additional investments in the field of electromobility."


Steve Cope, President, CEO and Director, Silver Viper

Steve Cope
President, CEO and Director | Silver Viper
1055 W Hastings St Suite 1130, V6E 2E9 Vancouver (CAN)

info@silverviperminerals.com

+1-604-687-8566

Interview with Silver Viper: Future price drivers and takeover fantasy


14. December 2020 | 12:37 CET

BYD, Almonty Industries, Alexion - Take advantage of the correction!

  • Investments
Photo credits: pixabay.com

It is here, the second hard lockdown due to the global Corona pandemic. After the broad market in the past few days announced a correction, there are again numerous opportunities to get more favorable stocks of great interest. Even sectors that have risen disproportionately, such as electromobility, hydrogen and e-commerce, are heading south—a new opportunity to bet on the winners of the future.

time to read: 3 minutes by Stefan Feulner


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


Clear target in sight

Unimpressed by the news of the past few days, the Canadian Company Almonty Industries is pursuing its goal of building the world's largest tungsten mine in Sangdong, South Korea. This mine would then produce 5% of the world's tungsten production and cover 30% of production outside China. The final contract with KfW-IPEX Bank was signed last week. The project financing is worth USD 75.1 million. A buyer for the tungsten concentrates, which are to be produced in Sangdong from 2022, has already been found. It is the Austrian Plansee Group, which is also providing EUR 30 million in bank guarantees to mitigate potential cost overruns.

Confidence-building measures

The fact that a long, trusting partnership is emerging here is reflected in the shareholder book. The Plansee Group takes over shares from the Company's CEO, making it the main shareholder. Deutsche Rohstoff AG remains on board with a current stake of 12.8%. Analyst Simon Scholes of First Equity Research celebrates this deal with a "buy" rating. His target price is CAD 1.45. Currently, Almonty's share price is at CAD 0.66, a potential doubling opportunity!

Vaccine candidate with record acquisition

AstraZeneca is still well in the global race for approval of a vaccine against the Coronavirus. Although the British Company has been left behind in the timetable by its competitors Moderna and the joint venture between BioNtech and Pfizer, a marketing authorization application could still be submitted within the next six weeks if the results of the trials are positive. Now the British pharmaceutical giant, formed in 1999 from the merger of Sweden's Astra with Britain's Zeneca, is looking to expand its portfolio.

Record acquisition to expand

The purchase of the US biotech Company Alexion is worth a whopping USD 39.0 billion to the British Company. In the process, AstraZeneca intends to pay a total of USD 175 per Alexion share in cash as well as in its own securities. With the acquisition, AstraZeneca aims to expand its immunology and rare diseases business. In 2019, Alexion generated sales of just under USD 5.0 billion in this division. The lion's share of this is accounted for by the drug Soliris. This drug is used to treat paroxysmal nocturnal hemoglobinuria, a rare, life-threatening disease that leads to the destruction of red blood cells. Currently, the British themselves have a stock market value of EUR 115.99 billion. The expansion of the product range makes sense, and the acquisition target promises great potential. Moreover, the British are still lagging in vaccine development. However, the demand will be so great that enormous sales can still be generated upon approval.

Strong figures confirm the trend

The electric car manufacturer BYD continues to deliver strong delivery figures. In November 2020, for example, a total of 53,943 vehicles were delivered to customers, more than 6,200 more than in the previous month. The main sales driver here was, of course, the New Energy Vehicle segment, which consists primarily of hybrid and all-electric vehicles. With 26,690 units, the Chinese recorded a healthy increase of well over 200% compared with the same period last year, when only 11,220 units were sold. By contrast, sales of cars with internal combustion engines fell by 9.4%.

Share too expensive

Arguing that the stock was overvalued, analysts at asset manager UBS lowered the stock from "neutral" to "sell." The "Build your dreams" share has received some advance praise in recent months, which is reflected in the significantly increased share price. Currently, the share price, which reached its high at EUR 22.39, is going through a first correction phase. At EUR 18.20, there is a broad support zone that has already been successfully defended once. The 50-day line is now also located in this area. If this zone holds, BYD could soon head north again.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

20. April 2021 | 09:45 CET | by Stefan Feulner

Varta, Sierra Growth, CureVac - Clear signals!

  • Investments

Sometimes, for various reasons, it takes longer before the positive developments of a Company are absorbed by the market and thus provide for price gains. It is currently similar to the precious metal gold, which is still in the consolidation phase. The facts such as national debt, inflation fears and the ultra-loose monetary policy of the central banks speak another clear language.

Read

20. April 2021 | 07:10 CET | by Carsten Mainitz

BioNTech, SunMirror, Steinhoff - Great News!

  • Investments

Shortly before the finish line, the going gets tough again. Many athletes and those who have to really "bite" in the last few meters before a deadline are probably familiar with this feeling. Everyday life in the Corona pandemic is also becoming more exhausting. Now, with BioNTech's announcement that it will double weekly vaccine dose deliveries to around 5.1 million units from the end of May, there may be a breakthrough in achieving herd immunity in Germany in the next few months. It is not only good news for the Company's shareholders but everyone. Below we present two other companies whose shareholders should be very pleased. Let us surprise you!

Read

15. April 2021 | 07:15 CET | by Stefan Feulner

Alibaba, The Place Holdings, CureVac - Great opportunities lie here!

  • Investments

The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?

Read